Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical. It also provides manufacturing of generic APIs, nutraceutical ingredients, and custom synthesis for big pharma. The company was founded by Murali Krishna Prasad Divi on October 12, 1990 and is headquartered in Hyderabad, India.
DIVI S LABORATORIES LTD financial statements, including revenue, expenses, and profit: The total revenue of DIVISLAB for the last quarter is 25.85 B INR, and it's 11.47% higher compared to the previous quarter. The net income of Q4 24 is 6.62 B INR.
DIVI S LABORATORIES LTD key financial stats and ratios: DIVISLAB price-to-sales ratio is 18.71. The company has an Enterprise Value to EBITDA ratio of 57.79. As of 2024 they employed 18.3 k people.
DIVI S LABORATORIES LTD dividends overview: DIVISLAB dividends are paid annually. The last dividend per share was 30.00 INR. As of today, Dividend Yield (TTM)% is 0.45%.
DIVI S LABORATORIES LTD earnings per share and revenue: DIVISLAB earnings per share for the last quarter are 24.90 INR whereas the estimation was 22.63 INR which accounts for 10.01% surprise. Company revenue for the same period amounts to 25.85 B INR despite the estimated figure of 25.62 B INR. Estimated earnings per share for the next quarter are 22.29 INR, and revenue is expected to reach 24.69 B INR. Also watch annual changes over time to get a bigger picture of DIVISLAB earnings per share and revenue dynamics.
DIVI S LABORATORIES LTD revenue breakdown overview: DIVI S LABORATORIES LTD revenue for the last year amounted to 93.60 B INR, the most of which — 93.60 B INR — came from its highest performing source at the moment, Active Pharmaceutical Ingredients and Intermediates, the year earlier bringing 78.45 B INR. The greatest contribution to the revenue figure was made by Europe — last year it brought DIVI S LABORATORIES LTD 33.57 B INR, and the year before that — 30.36 B INR.
Potential 50% Upside with Entry Price 6000, Target Price 9000, Timeframe 6-12 Months
Comments
Post a Comment